Ligands with its PDB code and its tanimoto calculated from the molecule, present in the database, which has for MMscode: MMs00030228
You can sort the columns by Ligand, Ligand name, PDB and Tanimoto.
You can sort the columns by Ligand, Ligand name, PDB and Tanimoto.
| Ligand | Ligand name | Chain | PDB | Tanimoto | Ligand in PDB |
|---|---|---|---|---|---|
| Ligand | Ligand name | Chain | PDB | Tanimoto | Ligand in PDB |
HMN | 2,4,6,7,8,9-HEXAHYDROXY-5-METHYLCARBOXAMIDO NONANOIC ACID | A,B,C,D | 1F73 | 0.76 |  |
IVS | 3-HYDROXY-6-METHYL-4-(3-METHYL- 2-(3-METHYL-2-(3-METHYL-BUTYRYLAMINO)- BUTYRYLAMINO)-BUTYRYLAMINO)-HEPTANOIC ACID ETHYL ESTER | A,B | 1ME6 | 0.71 | |
NAU | 4,4,6,7,8,9-HEXAHYDROXY-5-METHYLCARBOXAMIDONONANOIC ACID | A,C | 1F7B | 0.74 | |
ATI | N-(3-AMINO-2-HYDROXY-5-METHYLHEXANOYL)VALYLVALYLASPARTIC ACID | A | 1Y0Y | 0.72 | |
DYH | (2R,3aR,6S,7R,7aR)-2-[(2S)-2-amino- 2-carboxyethyl]-6-hydroxy-7-(methylamino)hexahydro- 2H-furo[3,2-b]pyran-2-carboxylic acid | A | 2ZNT | 0.75 | |
| DYH | (2R,3aR,6S,7R,7aR)-2-[(2S)-2-amino- 2-carboxyethyl]-6-hydroxy-7-(methylamino)hexahydro- 2H-furo[3,2-b]pyran-2-carboxylic acid | A,B,C,D | 3GBA | 0.75 | |
CNP | 2-PROPENYL-N-ACETYL-NEURAMIC ACID | A | 4SLI | 0.71 | |
MNA | 2-O-METHYL-5-N-ACETYL-ALPHA-D- NEURAMINIC ACID | A | 2P3I | 0.7 | |
| MNA | 2-O-METHYL-5-N-ACETYL-ALPHA-D- NEURAMINIC ACID | A | 1KQR | 0.7 | |
| MNA | 2-O-METHYL-5-N-ACETYL-ALPHA-D- NEURAMINIC ACID | A,B,C,D,E,F | 1HGH | 0.7 | |
| MNA | 2-O-METHYL-5-N-ACETYL-ALPHA-D- NEURAMINIC ACID | A,B | 2I2S | 0.7 | |
| MNA | 2-O-METHYL-5-N-ACETYL-ALPHA-D- NEURAMINIC ACID | A | 2P3J | 0.7 | |
| MNA | 2-O-METHYL-5-N-ACETYL-ALPHA-D- NEURAMINIC ACID | A,B,C,D,E,F | 1HGE | 0.7 | |
| MNA | 2-O-METHYL-5-N-ACETYL-ALPHA-D- NEURAMINIC ACID | A | 2P3K | 0.7 | |
AMK | (S)-4-AMINO-4-{(S)-1-[(S)-2-CARBAMOYL- 1-((S)-1-{(S)-[(1R,2R)-2-((S)-1- CARBOXY-ETHYLCARBAMOYL)-CYCLOPENTYL]- HYDROXY-METHYL}-3-METHYL-BUTYLCARBAMOYL)- ETHYLCARBAMOYL]-2-METHYL-PROPYLCARBAMOYL}- BUTYRIC ACID | A,B,C | 1YM4 | 0.78 | |
ABX | 5-[1-(ACETYLAMINO)-3-METHYLBUTYL]- 4-(METHOXYCARBONYL)PROLINE | A | 1XOE | 0.72 | |
AR9 | (2R,4S)-N-butyl-4-[(2S,5S,7R)-2,7- dimethyl-3,15-dioxo-1,4-diazacyclopentadecan- 5-yl]-4-hydroxy-2-methylbutanamide | A,B,C | 3DV1 | 0.71 | |
FSI | 5-(ACETYLAMINO)-2,6-ANHYDRO-3,5- DIDEOXY-3-FLUORONONONIC ACID | A | 2AH2 | 0.71 | |
| FSI | 5-(ACETYLAMINO)-2,6-ANHYDRO-3,5- DIDEOXY-3-FLUORONONONIC ACID | A | 2FHR | 0.71 | |
| FSI | 5-(ACETYLAMINO)-2,6-ANHYDRO-3,5- DIDEOXY-3-FLUORONONONIC ACID | A | 2A75 | 0.71 | |
| FSI | 5-(ACETYLAMINO)-2,6-ANHYDRO-3,5- DIDEOXY-3-FLUORONONONIC ACID | A,B | 2VK7 | 0.71 | |
MU2 | N-ACETYLMURAMYL-L-ALANYL-D-ISOGLUTAMINE | A | 2IXV | 0.75 | |
| MU2 | N-ACETYLMURAMYL-L-ALANYL-D-ISOGLUTAMINE | A | 2IXU | 0.75 | |
ITL | (3alpha,5alpha,8alpha)-3-[(N,N- bis{2-[bis(carboxymethyl)amino]ethyl}- L-gamma-glutamyl)amino]cholan-24- oic acid | A | 2K62 | 0.72 | |
2G0 | (2S)-1-[(2S)-6-amino-2-({[(2S,3S,4R,5S,6S)- 3,4,5-trihydroxy-6-methyltetrahydro- 2H-pyran-2-yl]acetyl}amino)hexanoyl]- N-[(1S)-1-carbamoyl-3-methylbutyl]pyrrolidine- 2-carboxamide | A,B,C,D | 3DCQ | 0.74 | |
AMN | 9-DEOXY-9-AMINO-2-O-METHYL-5-N- ACETYL-ALPHA-D-NEURAMINIC ACID | A,B,C,D,E,F | 1HGJ | 0.71 | |
ANA | 4-O-ACETYL-ALPHA-2-OMETHYL-5-N- ACETYL-ALPHA-D-NEURAMINIC ACID | A,B,C,D,E,F | 1HGI | 0.7 | |
IHN | N-(3-methylbutanoyl)-L-valyl-N- [(1R,2R)-4-{[(1R)-2-({(1R)-1-[(1R)- 2-carboxy-1-hydroxyethyl]-3-methylbutyl}amino)- 1-methyl-2-oxoethyl]amino}-2-hydroxy- 1-(2-methylpropyl)-4-oxobutyl]- L-valinamide | A | 3EMY | 0.74 | |
| IHN | N-(3-methylbutanoyl)-L-valyl-N- [(1R,2R)-4-{[(1R)-2-({(1R)-1-[(1R)- 2-carboxy-1-hydroxyethyl]-3-methylbutyl}amino)- 1-methyl-2-oxoethyl]amino}-2-hydroxy- 1-(2-methylpropyl)-4-oxobutyl]- L-valinamide | A | 2H6T | 0.74 | |
| IHN | N-(3-methylbutanoyl)-L-valyl-N- [(1R,2R)-4-{[(1R)-2-({(1R)-1-[(1R)- 2-carboxy-1-hydroxyethyl]-3-methylbutyl}amino)- 1-methyl-2-oxoethyl]amino}-2-hydroxy- 1-(2-methylpropyl)-4-oxobutyl]- L-valinamide | A,B | 1LS5 | 0.74 | |
| IHN | N-(3-methylbutanoyl)-L-valyl-N- [(1R,2R)-4-{[(1R)-2-({(1R)-1-[(1R)- 2-carboxy-1-hydroxyethyl]-3-methylbutyl}amino)- 1-methyl-2-oxoethyl]amino}-2-hydroxy- 1-(2-methylpropyl)-4-oxobutyl]- L-valinamide | A,B | 1SME | 0.74 | |
| IHN | N-(3-methylbutanoyl)-L-valyl-N- [(1R,2R)-4-{[(1R)-2-({(1R)-1-[(1R)- 2-carboxy-1-hydroxyethyl]-3-methylbutyl}amino)- 1-methyl-2-oxoethyl]amino}-2-hydroxy- 1-(2-methylpropyl)-4-oxobutyl]- L-valinamide | A,C | 1W6I | 0.74 | |
| IHN | N-(3-methylbutanoyl)-L-valyl-N- [(1R,2R)-4-{[(1R)-2-({(1R)-1-[(1R)- 2-carboxy-1-hydroxyethyl]-3-methylbutyl}amino)- 1-methyl-2-oxoethyl]amino}-2-hydroxy- 1-(2-methylpropyl)-4-oxobutyl]- L-valinamide | A,B | 1XDH | 0.74 | |
| IHN | N-(3-methylbutanoyl)-L-valyl-N- [(1R,2R)-4-{[(1R)-2-({(1R)-1-[(1R)- 2-carboxy-1-hydroxyethyl]-3-methylbutyl}amino)- 1-methyl-2-oxoethyl]amino}-2-hydroxy- 1-(2-methylpropyl)-4-oxobutyl]- L-valinamide | A,B | 2QZX | 0.74 | |
| IHN | N-(3-methylbutanoyl)-L-valyl-N- [(1R,2R)-4-{[(1R)-2-({(1R)-1-[(1R)- 2-carboxy-1-hydroxyethyl]-3-methylbutyl}amino)- 1-methyl-2-oxoethyl]amino}-2-hydroxy- 1-(2-methylpropyl)-4-oxobutyl]- L-valinamide | A | 1IZE | 0.74 | |
| IHN | N-(3-methylbutanoyl)-L-valyl-N- [(1R,2R)-4-{[(1R)-2-({(1R)-1-[(1R)- 2-carboxy-1-hydroxyethyl]-3-methylbutyl}amino)- 1-methyl-2-oxoethyl]amino}-2-hydroxy- 1-(2-methylpropyl)-4-oxobutyl]- L-valinamide | A,B | 1M43 | 0.74 | |
MLD | GLCNAC(BETA1-4)-MURNAC(1,6-ANHYDRO)- L-ALA-GAMMA-D-GLU-MESO-A2PM-D-ALA | A,X | 2F2L | 0.74 | |
| MLD | GLCNAC(BETA1-4)-MURNAC(1,6-ANHYDRO)- L-ALA-GAMMA-D-GLU-MESO-A2PM-D-ALA | A,B,C,D | 2CB3 | 0.74 | |
ABW | 5-[1-(ACETYLAMINO)-3-METHYLBUTYL]- 2,5-ANHYDRO-3,4-DIDEOXY-4-(METHOXYCARBONYL)PENTONIC ACID | A | 1XOG | 0.75 | |
CPQ | N,N-BIS(3-D-GLUCONAMIDOPROPYL)DEOXYCHOLAMIDE | A | 2REW | 0.75 | |
| CPQ | N,N-BIS(3-D-GLUCONAMIDOPROPYL)DEOXYCHOLAMIDE | A | 1IMX | 0.75 | |
| CPQ | N,N-BIS(3-D-GLUCONAMIDOPROPYL)DEOXYCHOLAMIDE | A | 1I7G | 0.75 | |